Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR.

Abstract

Sarcomas differ from carcinomas in their mesenchymal origin. Therapeutic advancements have come slowly, so alternative drugs and models are urgently needed. These studies report a new drug for sarcomas that simultaneously targets both tumor and tumor neovasculature. eBAT is a bispecific angiotoxin consisting of truncated, deimmunized Pseudomonas exotoxin… (More)
DOI: 10.1158/1535-7163.MCT-16-0637

Topics

4 Figures and Tables

Cite this paper

@article{Borgatti2017SafeAE, title={Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR.}, author={Antonella Borgatti and Joseph S Koopmeiners and Aaron L. Sarver and Amber L. Winter and Kathleen M. Stuebner and Deborah A. Todhunter and Anthony E. Rizzardi and Jonathan C. Henriksen and Stephen C. Schmechel and Colleen Forster and Jong-Hyuk Kim and Jerry Froelich and Jillian Walz and Michael S. Henson and Matthew Breen and Kerstin Lindblad-Toh and Felix Oh and Kristy Pilbeam and Jaime F Modiano and Daniel A. Vallera}, journal={Molecular cancer therapeutics}, year={2017}, volume={16 5}, pages={956-965} }